Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 445,314 shares, a drop of 24.1% from the December 15th total of 586,355 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 565,892 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 565,892 shares, the short-interest ratio is currently 0.8 days. Currently, 1.1% of the shares of the company are short sold.

Harvard Bioscience Trading Up 1.3%

NASDAQ HBIO opened at $0.59 on Tuesday. Harvard Bioscience has a 12 month low of $0.28 and a 12 month high of $1.98. The stock has a market cap of $26.18 million, a price-to-earnings ratio of -0.48 and a beta of 1.52. The company’s 50 day moving average is $0.68 and its two-hundred day moving average is $0.55.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HBIO. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HBIO. Williams & Novak LLC lifted its position in shares of Harvard Bioscience by 37.0% in the second quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 28,800 shares in the last quarter. AMH Equity Ltd raised its stake in Harvard Bioscience by 3.6% during the 2nd quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock valued at $1,557,000 after purchasing an additional 121,348 shares during the period. Pasadena Private Wealth LLC lifted its holdings in Harvard Bioscience by 23.2% in the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 45,872 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after purchasing an additional 78,276 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Harvard Bioscience by 139.7% in the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock worth $208,000 after purchasing an additional 276,372 shares during the period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.